L Pavone

Summary

Publications

  1. ncbi Outcome and prognostic factors during the course of primary small-vessel vasculitides
    Laura Pavone
    Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, and Dipartimento di Neuroscienze, Universita degli Studi di Parma, Parma, Italy
    J Rheumatol 33:1299-306. 2006
  2. ncbi Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma
    L Pavone
    Division of Nephrology and Dialysis, Guglielmo da Saliceto Hospital, Via Taverna, 49, 29100 Piacenza, Italy
    Med Oncol 26:38-44. 2009
  3. ncbi Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma
    C Buzio
    Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, Universita degli Studi di Parma, Parma, Italy
    Cancer 92:2286-96. 2001
  4. ncbi Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer
    L Pavone
    Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, , Italy
    Cancer Immunol Immunother 50:82-6. 2001

Collaborators

Detail Information

Publications4

  1. ncbi Outcome and prognostic factors during the course of primary small-vessel vasculitides
    Laura Pavone
    Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, and Dipartimento di Neuroscienze, Universita degli Studi di Parma, Parma, Italy
    J Rheumatol 33:1299-306. 2006
    ..To identify the prognostic factors of relapse and/or death during the course of primary small-vessel vasculitides (PSVV), and to differentiate their prognostic relevance by the type of vasculitis...
  2. ncbi Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma
    L Pavone
    Division of Nephrology and Dialysis, Guglielmo da Saliceto Hospital, Via Taverna, 49, 29100 Piacenza, Italy
    Med Oncol 26:38-44. 2009
    ..021) and similarly in the two groups of patients (P = 0.860); a reverse relation, even if not significant, was seen between the variation of NK-T cells and NK cells cytotoxicity (r = -0.39; P = 0.074)...
  3. ncbi Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma
    C Buzio
    Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, Universita degli Studi di Parma, Parma, Italy
    Cancer 92:2286-96. 2001
    ....
  4. ncbi Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer
    L Pavone
    Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, , Italy
    Cancer Immunol Immunother 50:82-6. 2001
    ..CONCLUSIONS: Long-term repeated cycles of low-dose immunotherapy induced repeated and significant expansion of one of the most important lymphocyte subsets for the non-MHC-restricted immune response to the tumour mass: CD3-CD56+ cells...